BUENA, N.J.--(BUSINESS WIRE)--IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based formulation and manufacturing company, today announced that it has submitted two additional abbreviated new drug applications (ANDAs) to the US FDA, bringing the company’s total number of submissions to eight. IGI President and CEO Charlie Moore commented, “We have now submitted eight ANDAs to the US FDA in just over two years. Our development pipeline remains full and we are gaining efficiency with each new project. Our team continues to execute on the product development front, while simultaneously growing our contract formulation and manufacturing business.” The development of ANDA products has successfully been integrated into the Company’s ongoing contract services business.
